DONATE

nAngioDerm participated in world congress TERMIS

Professor Elisabeth Engel from IBEC, coordinator of nAngioDerm European project, presented the advances of the project at the 6th world congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS2021). Professor Engel talked about cells-materials interactions to promote vascularization in one of the most important scientific conferences in the field of tissue engineering and regenerative medicine.

Dermoglass in the media

Elisabeth Engel from the Institute for Bioengineering of Catalonia (IBEC) and Professor at the Polytechnic University of Catalonia (UPC) appears in different media for the Dermoglass technology, the first project financed by the CaixaImpulse program to be licensed to a pharmaceutical company.

Dermoglass technology takes the leap into the pharmaceutical industry

Dermoglass becomes the first project funded by the CaixaImpulse program to be licensed to a pharmaceutical company, Laboratorios ERN. It is a new technology to tackle chronic ulcers developed by the research group “Biomaterials for Regenerative Therapies” led by Dr. Elisabeth Engel at the Institute for Bioengineering of Catalonia (IBEC), who is also Professor at Polytechnic University of Catalonia (UPC).

3D printed hydrogels for cancer immunotherapy T-cell growth

The new 3D hydrogels provide high rates of cell proliferation, as they mimic lymph nodes, where T-cells reproduce in vivo. A new project, led by researchers from ICMAB and IBEC, and with the collaboration of VHIO and UIC, wants to transfer this technology to hospitals.

Cancer immunotherapy is based on using and strengthening the patient’s own immune system to recognize and fight tumor cells, without damaging healthy tissues.

Elisabeth Engel at Santander Pioneros: it’s time to support science

Three protagonists of the medical research field in Spain debated in a new edition of the “Pioneros Santander” forum, organized virtually by El País Retina. Elisabeth Engel, group leader of Biomaterials for regenerative therapies at IBEC, Rocío Arroyo, CEO of Amadix and Eduardo Jorgensen, of Medicsen, also CEO, agreed to celebrate the greatest interest in their work area, the intersection between science, technology and health, but at the same time they were cautious: there are no shortcuts in research, neither before Covid-19 nor after.